parapsoriasis: one of a group of skin disorders that are characterized primarily by their resemblance to psoriasis (red, scaly lesions), rather than by their underlying etiology. Neoplasms can develop from parapsoriasis. For example, it can develop into cutaneous T-cell lymphoma.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
178 |
4. Check minimum number of eventsNone |
178 |
5. Include endpointsNone |
178 |
6. Filter based on genotype QC (FinnGen only) |
159 |
Control definitions (FinnGen only)
- Control exclude
- L12_PAPULOSQUAMOUS
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Other and unspecified parapsoriasis
based on the number of shared cases.
Similar with more cases:
- Parapsoriasis
- Papulosquamous disorders
- Diseases of the skin and subcutaneous tissue
- Any operation in hilmo
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1163 | 429 | 723 |
| Only index persons | 1003 | 377 | 626 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.01 | 0.02 |
| Only index persons | 0.02 | 0.01 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 58.23 | 55.63 | 59.80 |
| Only index persons | 58.11 | 55.18 | 59.87 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 159 | 64 | 95 |
| Unadjusted period prevalence (%) | 0.04 | 0.02 | 0.04 |
| Median age at first event (years) | 56.79 | 57.96 | 56.01 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 165
- Matched controls
- 1650
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L41.9
ICD-10 Finland
Parapsoriasis, unspecified
+∞
115.6
97
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
21.3
89.8
91
90
L41.8
ICD-10 Finland
Other parapsoriasis
+∞
66.2
59
*
D07AB08
ATC
desonide; topical
9.9
42.1
62
95
E000001, ,
ATC
7.5
36.6
78
177
D07AC01
ATC
betamethasone; topical
7.6
35.2
118
409
L30.9
ICD-10 Finland
Dermatitis, unspecified
6.9
34.0
80
198
E0000UV, ,
ATC
7.5
32.6
124
473
E000002, ,
ATC
8.0
29.0
47
78
L40.0
ICD-10 Finland
Psoriasis vulgaris
66.9
24.9
28
5
L41.3
ICD-10 Finland
Small plaque parapsoriasis
+∞
24.6
23
*
C84.0
ICD-10 Finland
Mycosis fungoides
126.1
21.1
22
*
D07AC13
ATC
mometasone; topical
4.5
20.0
79
282
D07AD01
ATC
clobetasol; topical
4.7
16.6
48
133
D07AB02
ATC
hydrocortisone butyrate; topical
3.6
14.4
77
325
69621
ICD-8 Finland
Psoriasis and similar disorders, Parapsoriasis guttata
+∞
13.7
13
*
WXQ27
NOMESCO Finland
UVB narrow spectrum light therapy
54.6
13.1
15
*
L41.4
ICD-10 Finland
Large plaque parapsoriasis
+∞
12.7
12
*
D07AA02
ATC
hydrocortisone; topical
4.0
11.7
39
118
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
3.3
11.3
58
233
Z2221
NOMESCO Finland
Medical doctor
3.0
10.0
64
289
D05AX52
ATC
calcipotriol, combinations; topical
9.6
9.6
19
22
D07XC01
ATC
betamethasone; topical
4.0
9.1
29
84
D02AE01
ATC
carbamide; topical
5.2
9.1
20
43
D02AX
ATC
Other emollients and protectives
11.7
9.0
16
15
D05BB02
ATC
acitretin; oral
29.3
8.6
11
*
E000006, ,
ATC
4.9
8.1
19
43
D05AX02
ATC
calcipotriol; topical
14.0
8.0
13
10
E000003, ,
ATC
8.1
7.9
17
23
E000007, ,
ATC
4.9
7.4
17
38
9700/3-C44.9
ICD-O-3
Mycosis fungoides of skin, NOS
+∞
7.3
7
*
XQ848
NOMESCO Finland
Dermatological photography
7.3
7.0
16
24
L40.9
ICD-10 Finland
Psoriasis, unspecified
41.8
6.8
8
*
A06AC01
ATC
ispaghula (psylla seeds); oral
2.5
6.5
57
292
D07AC14
ATC
methylprednisolone aceponate; topical
6.4
6.5
16
27
Z3231
NOMESCO Finland
Registered nurse
2.4
6.5
60
316
L41.1
ICD-10 Finland
Pityriasis lichenoides chronica
+∞
6.3
6
*
69623
ICD-8 Finland
Psoriasis and similar disorders, Parapsoriasis varioliformis
+∞
6.3
6
*
69619
ICD-8 Finland
Psoriasis and similar disorders, Psoriasis alia sive NUD (vulgaris)
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
64
215
4.23
17.22
5.8
4.8
218.69
242.24
u/l
1.71
64
202
129
835
3.50
10.64
13.0
10.7
4.05
4.19
e9/l
0.30
122
725
24
75
3.57
6.73
1.4
1.8
2.86
3.19
g/l
0.90
24
68
24
78
3.43
6.34
1.4
1.8
3.47
3.69
g/l
0.37
24
71
70
458
1.92
3.95
4.0
3.4
0.17
0.59
e6/l
1.61
55
334
5
5
10.25
3.00
3.2
1.4
581.80
1014.40
u/ml
—
5
5
49
319
1.76
2.65
1.4
1.3
0.92
1.55
u/ml
0.63
13
91
101
799
1.68
2.64
9.8
7.4
1.22
1.21
mmol/l
1.51
91
691
44
278
1.79
2.63
3.0
3.1
0.88
0.88
e6/l
0.00
28
142
5
7
7.32
2.56
1.6
2.4
124.80
92.14
%
—
5
7
144
1274
2.02
2.40
5.9
5.3
1.88
2.03
mu/l
1.00
133
1157
87
676
1.61
2.34
2.7
2.1
95.16
96.26
pmol/l
0.09
51
354
22
114
2.07
2.34
4.1
4.1
94.95
89.36
ng/l
0.14
22
97
23
122
2.03
2.30
1.7
1.6
—
—
—
0
0
40
256
1.74
2.27
3.3
3.3
2.25
2.01
e6/l
0.06
24
122
48
324
1.68
2.25
5.5
3.1
2.45
2.46
mmol/l
0.30
42
287
40
260
1.71
2.14
15.6
6.7
103.10
104.33
mmol/l
0.77
40
260
10
37
2.81
2.11
1.1
1.2
—
—
—
0
0
10
38
2.73
2.04
1.5
1.3
—
—
—
0
0
74
567
1.55
2.03
3.4
3.4
1319.57
1304.71
ng/l
0.02
64
489
157
1469
2.42
1.96
34.1
24.9
83.55
83.41
umol/l
0.02
157
1451
5
12
4.26
1.83
1.2
1.1
—
—
—
0
0
69
535
1.50
1.73
6.2
3.7
2.34
2.35
mmol/l
0.27
64
487
21
120
1.86
1.72
2.9
3.1
54.43
58.86
ml/min/173m2
—
7
51
95
787
1.49
1.71
4.5
4.1
0.00
0.00
estimate
-0.00
19
181
52
387
1.50
1.57
3.0
2.2
2.44
2.96
mg/l
0.77
47
337
8
33
2.50
1.56
1.5
1.3
—
—
—
0
0
38
265
1.56
1.53
4.0
2.0
29.01
29.10
s
0.04
38
258
96
810
1.44
1.50
4.6
4.1
0.00
0.00
estimate
-0.00
19
165
95
801
1.44
1.48
4.5
4.0
0.00
8.73
estimate
0.50
19
186
119
1048
1.49
1.46
4.9
4.2
15.38
14.94
pmol/l
1.06
111
946
149
1381
1.81
1.46
5.6
5.6
1.40
1.42
mmol/l
0.26
141
1264
25
159
1.67
1.45
3.4
3.2
4.90
4.33
kpa
0.73
25
152
149
1383
1.80
1.42
26.5
19.0
23.28
25.26
mg/l
0.37
127
1165
5
17
3.00
1.37
1.2
1.2
—
—
—
0
0
5
17
3.00
1.37
1.2
1.2
—
—
—
0
0
5
17
3.00
1.37
1.2
1.2
—
—
—
0
0
5
17
3.00
1.37
1.2
1.2
—
—
—
0
0
12
61
2.04
1.36
1.3
1.4
—
—
—
0
0
9
42
2.21
1.36
1.2
1.2
—
—
—
0
0
9
42
2.21
1.36
1.2
1.2
—
—
—
0
0
42
308
1.49
1.35
4.2
3.9
371.85
453.14
ng/l
0.10
33
259
17
101
1.76
1.25
3.0
2.9
0.50
0.62
%
1.07
17
101
54
422
1.42
1.24
3.4
3.1
356.36
355.80
umol/l
0.01
47
360
144
1337
1.61
1.21
4.8
4.8
1.28
1.29
mmol/l
0.07
132
1212
148
1384
1.67
1.19
5.9
5.7
4.44
4.51
mmol/l
0.35
141
1280
5
20
2.54
1.16
1.2
1.2
—
—
—
0
0
36
264
1.47
1.15
1.4
1.3
20.89
37.37
iu/ml
—
9
82
17
104
1.71
1.14
3.0
2.9
1.01
1.15
%
0.42
17
104
17
104
1.71
1.14
2.8
2.6
—
11.84
—
0
9
7
30
2.39
1.14
2.7
1.5
—
—
—
0
0
7
30
2.39
1.14
2.7
1.5
—
—
—
0
0
32
230
1.49
1.13
1.3
1.3
22.76
17.65
u/ml
0.15
15
75
27
187
1.53
1.13
4.2
4.0
5.71
5.69
kpa
0.05
27
181
5
21
2.42
1.10
1.2
1.5
—
—
—
0
0
150
1413
1.68
1.10
6.8
6.5
2.58
2.62
mmol/l
0.22
144
1301
21
142
1.55
0.98
2.5
3.0
27.60
31.89
u/l
0.45
15
115
16
101
1.65
0.98
5.6
3.9
25.06
24.43
mmol/l
0.37
16
101
6
27
2.27
0.94
10.3
4.4
—
—
—
0
0
6
28
2.18
0.92
5.0
3.3
6.57
10.59
pmol/l
—
6
28
14
87
1.67
0.91
2.2
1.9
—
—
—
0
0
8
42
1.95
0.90
1.0
1.2
—
—
—
0
0
144
1357
1.48
0.89
7.3
7.3
39.48
40.51
mmol/mol
0.89
138
1275
27
198
1.43
0.87
2.7
2.0
—
—
—
0
0
51
418
1.32
0.85
3.7
3.4
0.51
0.79
ug/l
4.63
34
280
85
747
1.28
0.83
2.4
2.6
—
—
—
0
0
0
24
0.00
0.80
0.0
3.6
—
25.92
—
0
13
34
266
1.35
0.77
2.6
2.0
—
—
—
0
0
144
1366
1.43
0.76
5.4
5.7
6.06
6.10
mmol/l
0.15
135
1250
5
24
2.12
0.75
1.2
1.1
—
—
—
0
0
5
24
2.12
0.75
1.0
1.0
—
—
—
0
0
7
38
1.88
0.74
1.6
1.4
—
0.01
—
0
8
27
207
1.36
0.69
2.7
1.9
—
—
—
0
0
65
563
1.25
0.69
5.1
4.9
20.76
21.92
%
0.24
30
288
13
86
1.56
0.68
2.1
1.4
—
—
—
0
0
11
70
1.61
0.67
1.0
1.0
—
—
—
0
0
23
173
1.38
0.66
3.0
3.8
—
—
—
0
0
53
454
1.25
0.61
3.9
3.7
0.00
0.00
estimate
-0.00
17
152
42
352
1.26
0.58
2.7
1.7
1.01
1.71
mg/l
1.49
35
284
6
38
1.60
0.55
1.2
1.3
—
—
—
0
0
10
66
1.55
0.54
2.8
3.0
—
—
—
0
0
42
357
1.24
0.52
5.0
2.5
—
—
—
0
0
7
45
1.58
0.49
1.3
1.6
—
—
—
0
0
77
700
1.19
0.48
7.2
5.8
2.06
2.59
ug/l
0.44
69
628
68
612
1.19
0.47
4.2
4.0
0.00
0.00
estimate
-0.00
18
155
11
77
1.46
0.47
4.0
3.9
1.02
1.02
ratio
0.05
11
72
7
49
1.45
0.46
1.1
1.2
—
—
—
0
0
7
49
1.45
0.46
1.3
1.4
—
—
—
0
0
63
566
1.18
0.44
4.9
3.8
4.56
9.01
mg/mmol
1.00
43
348
10
137
0.71
0.41
1.4
1.4
—
—
—
0
0
0
17
0.00
0.41
0.0
1.9
—
—
—
0
0
0
17
0.00
0.41
0.0
1.9
—
—
—
0
0
0
18
0.00
0.40
0.0
2.0
—
—
—
0
0
5
35
1.44
0.39
1.0
1.3
—
—
—
0
0
73
671
1.16
0.38
4.3
2.9
—
—
estimate
—
0
0
20
163
1.26
0.36
1.6
2.2
1.82
1.54
%
0.60
15
139
72
666
1.14
0.33
4.5
4.3
45.75
43.91
ng/l
0.04
52
525
6
47
1.29
0.32
1.0
1.2
—
1.93
—
0
9
6
47
1.29
0.32
1.8
1.4
—
—
—
0
0
23
195
1.21
0.30
4.1
4.0
7.67
9.40
umol/l
0.26
18
173
31
277
1.15
0.23
1.7
1.7
1059.86
1235.77
nmol/l
0.73
24
208
19
219
0.85
0.22
21.4
7.1
0.97
0.93
mmol/l
0.02
19
183
5
42
1.20
0.21
2.4
1.8
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
4.6
—
74.70
—
0
10
0
12
0.00
0.21
0.0
2.3
—
—
—
0
0
98
942
1.10
0.20
3.4
3.7
49.72
55.47
u/l
0.33
93
879
6
48
1.26
0.20
2.0
1.4
—
—
—
0
0
6
50
1.21
0.20
1.2
1.6
—
—
—
0
0
64
605
1.09
0.19
2.4
2.0
1.48
1.35
mmol/l
0.57
56
485
15
172
0.86
0.16
8.5
7.7
—
—
—
0
0
15
131
1.16
0.15
1.1
1.4
—
—
—
0
0
7
86
0.81
0.15
4.0
3.7
124.43
2947.62
u/ml
—
7
71
53
502
1.08
0.14
2.4
2.8
72.74
74.20
u/l
0.02
46
467
12
104
1.17
0.12
32.6
7.9
27.11
24.60
mmol/l
1.80
12
104
20
218
0.91
0.11
20.3
7.0
5.11
5.06
kpa
0.07
20
211
20
218
0.91
0.11
20.2
7.0
11.30
11.73
kpa
0.25
20
212
5
44
1.14
0.10
2.2
1.7
—
—
—
0
0
5
46
1.09
0.09
2.2
2.0
—
—
—
0
0
35
333
1.06
0.08
4.3
4.3
1.02
1.02
kg/l
0.62
20
226
6
72
0.83
0.08
1.8
1.6
—
—
—
0
0
49
505
0.96
0.06
4.4
3.8
32.98
35.54
u/l
0.25
49
472
17
181
0.93
0.05
1.6
1.5
—
—
—
0
0
32
330
0.96
0.03
2.0
1.9
459.50
447.43
pmol/l
0.10
26
278
46
455
1.02
0.00
4.6
4.1
0.00
0.00
estimate
-0.00
19
167
0
8
0.00
0.00
0.0
1.4
—
19.38
—
0
8
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
2.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
58.88
—
0
8
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
66
0.91
-0.00
5.2
2.3
864.67
1013.29
ug/l
—
6
59
0
5
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
5
56
0.89
-0.00
1.2
1.2
—
—
—
0
0
6
67
0.89
-0.00
1.7
1.5
—
—
—
0
0
0
9
0.00
-0.00
0.0
4.8
—
4.60
—
0
9
0
6
0.00
-0.00
0.0
2.8
—
13.62
—
0
6
0
5
0.00
-0.00
0.0
1.6
—
16.36
—
0
5
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
4.8
—
10.40
—
0
9
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
10.80
—
0
5
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.9
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_PARAPSO_RETIFORM and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_PARAPSO_RETIFORM | 1.069 [0.8, 1.43] | 0.653 |
| Birth year | 0.993 [0.98, 1.0] | 0.156 |
During the follow-up period (1.1.1998 — 31.12.2019), 59 out of 274 females with L12_PARAPSO_RETIFORM died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_PARAPSO_RETIFORM | 0.92 [0.76, 1.11] | 0.388 |
| Birth year | 0.985 [0.98, 0.99] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 139 out of 529 males with L12_PARAPSO_RETIFORM died.
Mortality risk
Mortality risk for people of age
years, who have L12_PARAPSO_RETIFORM.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.084% | 0.16% |
| 5 | 0.627% | 0.949% |
| 10 | 1.432% | 2.37% |
| 15 | 2.799% | 4.725% |
| 20 | 5.179% | 8.278% |
Relationships between endpoints
↥Index endpoint: L12_PARAPSO_RETIFORM – Other and unspecified parapsoriasis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data